5-Hour time window for intravenous thrombolysis with recombinant tissue- Type plasminogen activator is established firmly

Stroke

Volumn 45, Issue 3, 2014, Pages 912-913

  Schellinger, Peter D ^a   Kohrmann, Martin ^b  

^a KLINIKUM MINDEN   (Germany)

^b UNIVERSITY HOSPITAL ERLANGEN   (Germany)

Author keywords

Controlled clinical trials; Randomized; Stroke; Thrombolytic therapy

Indexed keywords

ALTEPLASE; FIBRINOLYTIC AGENT; TISSUE PLASMINOGEN ACTIVATOR;

BRAIN ISCHEMIA; CLINICAL PRACTICE; DRUG APPROVAL; DRUG EFFICACY; DRUG SAFETY; EUROPEAN MEDICINES AGENCY; FIBRINOLYTIC THERAPY; HUMAN; MALPRACTICE; NATIONAL INSTITUTES OF HEALTH STROKE SCALE; PATIENT SELECTION; PRACTICE GUIDELINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SHORT SURVEY; TIME TO TREATMENT; TREATMENT DURATION; ARTICLE; CEREBROVASCULAR ACCIDENT; CONTROLLED CLINICAL TRIALS, RANDOMIZED; INTRAVENOUS DRUG ADMINISTRATION; LACUNAR STROKE; METHODOLOGY; TIME;

CONTROLLED CLINICAL TRIALS, RANDOMIZED; STROKE; THROMBOLYTIC THERAPY;

FIBRINOLYTIC AGENTS; GUIDELINES AS TOPIC; HUMANS; INJECTIONS, INTRAVENOUS; STROKE; STROKE, LACUNAR; THROMBOLYTIC THERAPY; TIME FACTORS; TISSUE PLASMINOGEN ACTIVATOR;

EID: 84899154701     PISSN: 00392499     EISSN: 15244628     Source Type: Journal    
DOI: 10.1161/STROKEAHA.113.002700     Document Type: Short Survey

References (5)

1. Jauch EC, Saver JL, Adams HP Jr, Bruno A, Connors JJ, Demaerschalk BM, et al; American Heart Association Stroke Council; Council on Cardiovascular Nursing; Council on Peripheral Vascular Disease; Council on Clinical Cardiology. Guidelines for the early management of patients with acute ischemic stroke: A guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2013;44:870-947.
2. Hacke W, Kaste M, Bluhmki E, Brozman M, Devalos A, Guidetti D, et al; ECASS Investigators. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med. 2008;359:1317-1329.
3. Frank B, Grotta JC, Alexandrov AV, Bluhmki E, Lyden P, Meretoja A, et al; VISTA Collaborators. Thrombolysis in stroke despite contraindications or warnings? Stroke. 2013;44:727-733.
4. Sandercock P, Wardlaw JM, Lindley RI, Dennis M, Cohen G, Murray G et al. The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the third international stroke trial [ist-3]): A randomised controlled trial. Lancet. 2012;379:2352-2363.
5. Saver JL, Smith EE, Fonarow GC, Reeves MJ, Zhao X, Olson DM, et al; GWTG-Stroke Steering Committee and Investigators. The "golden hour" and acute brain ischemia: presenting features and lytic therapy in >30, 000 patients arriving within 60 minutes of stroke onset. Stroke. 2010;41:1431-1439.